City

Milano (1)

Monza (1)

Shenzhen (1)

Condition

Chronic (2)

Leukemia (2)

Myelogenous (2)

BCR-ABL (Breakpoint Cluster Region-abelson Murine Leukemia) (1)

BCR-ABL Positive (1)

Positive (1)

Overall Status

Completed (1)

Recruiting (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

Shenzhen Second People's Hospital (1)

University of Milano Bicocca (1)

Collaborator

IRCCS San Raffaele (1)

Intervention

bone marrow cells (1)

bone marrow transplant (1)

bosutinib (1)

Study Documents

Intervention Type

drug (1)

procedure (1)

Funder Type

Other (2)

Study Type

Interventional (1)

Observational (1)

myelogenous

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

TKI Discontinuation in CML Patients of China

Recruiting

Leukemia
+4 more

Shenzhen, Guangdong, China

Shenzhen Second People's Hospital

Mar 15, 2022

Leukemia, Myelogenous, Chronic Trial in Monza, Milano (Bosutinib, Bone Marrow Transplant, Bone Marrow cells)

Completed

Leukemia
+3 more

Bosutinib
+2 more

Monza, Italy/MB, Italy
+1 more

Nov 3, 2020